title: Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy.
abstract: OBJECTIVE
  To investigate whether magnetic resonance imaging (MRI) findings, when converted into a scoring system, can predict the biochemical recurrence of prostate cancer after radical prostatectomy (RP).
  
  
  METHODS
  Between January 2000 and October 2004, 610 patients with biopsy-confirmed prostate cancer had MRI before RP, with whole-mount step-sectioning of the pathology sample. MRI findings were retrospectively scored on a seven-point scale based on Tumour-Node-Mestastasis staging (1, no tumour seen, to 7, lymph node metastasis). MRI scores were added to published 5- and 10-year clinical preoperative nomograms for predicting recurrence. The predictive accuracy of MRI was quantified as the differences in bootstrap-corrected concordance indices of the models with and without MRI.
  
  
  RESULTS
  As of August 2007, 64 (10.5%) patients had a biochemical recurrence. MRI scores were associated with recurrence (P < 0.001) with hazard ratios of 1.76 and 1.81 in the 5- and 10-year models, respectively. Actual recurrence rates by MRI score were: 1, 0%; 2, 4.5%; 3, 9%; 4, 24.1%; 5, 33.3%; 6, 69.2%; 7, 100%. When MRI was added, the concordance indices of the 5- and 10-year models increased, from 0.762 to 0.776 (P = 0.081) and 0.773 to 0.788 (P = 0.107), respectively; the improvement was not significant.
  
  
  CONCLUSIONS
  The MRI scoring system devised was a strong predictor of biochemical recurrence after RP. Although MRI did not provide added prognostic value to standard clinical nomograms, in centres where MRI is used routinely, it might increase the confidence of the clinician in assessing the risk of recurrence by contributing supporting data.
authors.affiliation: Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Fuchsjäger
authors.forename: Amita
authors.initials: A
authors.lastname: Shukla-Dave
authors.forename: Hedvig
authors.initials: H
authors.lastname: Hricak
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Karim
authors.initials: K
authors.lastname: Touijer
authors.forename: John F
authors.initials: JF
authors.lastname: Donohue
authors.forename: James A
authors.initials: JA
authors.lastname: Eastham
authors.forename: Michael W
authors.initials: MW
authors.lastname: Kattan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000175:diagnosis*; D049451:Nomograms; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000601:surgery; D012189:Retrospective Studies
chemical_list: D017430:Prostate-Specific Antigen